DK2956471T3 - Il-1beta-hæmmersammensætning og anvendelse deraf - Google Patents

Il-1beta-hæmmersammensætning og anvendelse deraf Download PDF

Info

Publication number
DK2956471T3
DK2956471T3 DK13875211.8T DK13875211T DK2956471T3 DK 2956471 T3 DK2956471 T3 DK 2956471T3 DK 13875211 T DK13875211 T DK 13875211T DK 2956471 T3 DK2956471 T3 DK 2956471T3
Authority
DK
Denmark
Prior art keywords
inhibitor composition
1beta
1beta inhibitor
composition
inhibitor
Prior art date
Application number
DK13875211.8T
Other languages
English (en)
Inventor
Yan Lavrovsky
Ting Xu
Alexey Repik
Tao Xu
Vasily Ignatiev
Mikhail Samsonov
Original Assignee
R Pharm Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51354448&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2956471(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by R Pharm Int Llc filed Critical R Pharm Int Llc
Application granted granted Critical
Publication of DK2956471T3 publication Critical patent/DK2956471T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
DK13875211.8T 2013-02-15 2013-02-15 Il-1beta-hæmmersammensætning og anvendelse deraf DK2956471T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/026349 WO2014126582A1 (en) 2013-02-15 2013-02-15 IL-1β INHIBITOR COMPOSITION AND USE THEREOF

Publications (1)

Publication Number Publication Date
DK2956471T3 true DK2956471T3 (da) 2024-05-21

Family

ID=51354448

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13875211.8T DK2956471T3 (da) 2013-02-15 2013-02-15 Il-1beta-hæmmersammensætning og anvendelse deraf

Country Status (21)

Country Link
EP (2) EP2956471B1 (da)
JP (1) JP6225197B2 (da)
KR (1) KR101989551B1 (da)
CN (1) CN105431448B (da)
AU (1) AU2013378122B2 (da)
BR (1) BR112015019729B1 (da)
DK (1) DK2956471T3 (da)
EA (1) EA033269B1 (da)
FI (1) FI2956471T3 (da)
HK (1) HK1219281A1 (da)
IL (1) IL240553B (da)
LT (1) LT2956471T (da)
MX (1) MX2015010438A (da)
NZ (1) NZ710900A (da)
PH (1) PH12015501796A1 (da)
PL (1) PL2956471T3 (da)
PT (1) PT2956471T (da)
RS (1) RS65559B1 (da)
SG (1) SG11201506389YA (da)
SI (1) SI2956471T1 (da)
WO (1) WO2014126582A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101989551B1 (ko) 2013-02-15 2019-09-30 알-팜 인터내셔널, 엘엘씨. IL-1β 억제제 조성물 및 이의 용도
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
CN104725514A (zh) * 2015-02-06 2015-06-24 中国药科大学 新型il23拮抗剂
EP3638700B1 (en) * 2017-06-14 2024-07-24 Dingfu Biotarget Co., Ltd Proteinaceous heterodimer and use thereof
WO2019067639A1 (en) 2017-09-26 2019-04-04 Regeneron Pharmaceuticals, Inc. TREATMENT OF INFLAMMATORY CONDITIONS BY ADMINISTRATION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN
JP2023527171A (ja) * 2020-05-22 2023-06-27 アール-ファーム・オーバーシーズ・インコーポレイテッド IL-1βのIL1-R1由来のインヒビターおよびその使用
KR20220014531A (ko) 2020-07-29 2022-02-07 (주)메디톡스 헤테로이량체 Fc 융합 단백질, 및 관련 조성물, 용도 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
SI2314623T1 (sl) * 2005-06-21 2012-11-30 Xoma Technology Ltd IL beta vezavna protitelesa in njihovi fragmenti
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
JP6157046B2 (ja) * 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
US9624291B2 (en) * 2011-03-17 2017-04-18 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
KR101989551B1 (ko) 2013-02-15 2019-09-30 알-팜 인터내셔널, 엘엘씨. IL-1β 억제제 조성물 및 이의 용도

Also Published As

Publication number Publication date
LT2956471T (lt) 2024-06-10
JP2016513106A (ja) 2016-05-12
CN105431448A (zh) 2016-03-23
EA201500842A1 (ru) 2016-02-29
SI2956471T1 (sl) 2024-06-28
KR20160048028A (ko) 2016-05-03
IL240553B (en) 2021-02-28
PH12015501796B1 (en) 2015-11-09
SG11201506389YA (en) 2015-09-29
NZ710900A (en) 2019-09-27
FI2956471T3 (fi) 2024-05-13
HK1219281A1 (zh) 2017-03-31
PT2956471T (pt) 2024-05-27
BR112015019729B1 (pt) 2023-01-24
AU2013378122B2 (en) 2019-05-02
PL2956471T3 (pl) 2024-06-24
WO2014126582A1 (en) 2014-08-21
EP2956471B1 (en) 2024-04-10
EP2956471A4 (en) 2019-11-13
EA033269B1 (ru) 2019-09-30
IL240553A0 (en) 2015-10-29
RS65559B1 (sr) 2024-06-28
KR101989551B1 (ko) 2019-09-30
CN105431448B (zh) 2019-08-27
PH12015501796A1 (en) 2015-11-09
AU2013378122A1 (en) 2015-08-27
MX2015010438A (es) 2016-05-05
BR112015019729A2 (pt) 2017-07-18
EP2956471A1 (en) 2015-12-23
JP6225197B2 (ja) 2017-11-01
EP4050019A1 (en) 2022-08-31

Similar Documents

Publication Publication Date Title
DK3043784T3 (da) Arylethere og anvendelser deraf
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3052485T3 (da) Heterocykliske forbindelser og anvendelser deraf
DK3381917T3 (da) Imidazopyridinforbindelser og anvendelser deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK2970132T3 (da) Argininmethyltransferaseinhibitorer og anvendelser deraf
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK2968173T3 (da) Heterocykliske forbindelser og anvendelser deraf
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3060200T3 (da) Tyrosinderivater og sammensætninger dermed
DK3030519T3 (da) Tricykliske benzoxaborol-forbindelser og anvendelser deraf
DK3011041T3 (da) Biodieselsammensætning og dermed forbundet fremgangsmåde og produkter
DK3058936T3 (da) Peptidsammensætning og anvendelser deraf
DK3326642T3 (da) Langtidsvirkende koagulationsfaktorer og brugen deraf
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK2958926T3 (da) Epidithiodioxopiperazinforbindelse eller derivater deraf og anvendelse deraf
HK1219281A1 (zh) β抑制劑組合物及其用途
DK2941268T3 (da) Selektive nox-1-inhibitor-peptider og anvendelser deraf